丹参川芎嗪注射液治疗冠心病的临床联合用药特征研究
|
摘要
目的探讨丹参川芎嗪注射液用于冠心病人群的临床应用及合并用药特征,以期提高本品临床用药合理性,为后续前瞻研究提供证据。方法提取全国19家三甲医院使用丹参川芎嗪注射液且诊断为冠状动脉粥样硬化性心脏病的电子医疗数据,运用Apriori关联规则算法对联合用药信息进行挖掘,探索临床联合用药特征。结果4 545例使用丹参川芎嗪注射液的冠心病患者纳入研究,平均年龄72.48岁;男性多于女性;单次用药剂量以10 mL及以上者占大多数;用药疗程以3 d以内为主;临床上常用的联合药物类别包括抗凝溶栓及抗血小板药、降脂药、抗心绞痛药、中药活血化瘀剂等。结论丹参川芎嗪注射液治疗冠心病的临床应用人群特征明确,与流行病学一致;临床用药剂量大多高于品种说明书用量,而使用疗程较短,存在一定的不合理之处,需要临床医生警惕。
Objective To analyze the application and drug combination characteristics of Danshen Chuanxiongqin Injection in coronary heart disease in the real world based on hospital information system database, provide reference for clinical application of breed, and provide reference for prospective study. Methods The electronic medical data of Danshen Chuanqiongqin Injection in 19 hospitals and the diagnosis of coronary atherosclerotic heart disease were extracted, and the apriori association rule algorithm was applied to explore the information of combined medication and explore the potential combination medication rule. Results The study included 4 545 cases of patients with coronary heart disease using Danshen Chuanxiongqin Injection, with an average age of 72.48 years; more men than women; single dose to 10 mL and above accounted for the majority; the course of treatment in 3 days; the common clinical combined drug categories include anticoagulation thrombolysis and antiplatelet agents, lipidlowering drugs, anti angina drugs, and Chinese materia medica for activating blood circulation to dissipate blood stasis. Conclusion The clinical application in the treatment of coronary heart disease population characteristics and epidemiology of real world Danshen Chuanxiongqin Injection clear, consistent; the clinical dose is mostly higher than that of varieties specification definition, and use a shorter course of treatment, worthy of attention.
Objective To analyze the application and drug combination characteristics of Danshen Chuanxiongqin Injection in coronary heart disease in the real world based on hospital information system database, provide reference for clinical application of breed, and provide reference for prospective study. Methods The electronic medical data of Danshen Chuanqiongqin Injection in 19 hospitals and the diagnosis of coronary atherosclerotic heart disease were extracted, and the apriori association rule algorithm was applied to explore the information of combined medication and explore the potential combination medication rule. Results The study included 4 545 cases of patients with coronary heart disease using Danshen Chuanxiongqin Injection, with an average age of 72.48 years; more men than women; single dose to 10 mL and above accounted for the majority; the course of treatment in 3 days; the common clinical combined drug categories include anticoagulation thrombolysis and antiplatelet agents, lipidlowering drugs, anti angina drugs, and Chinese materia medica for activating blood circulation to dissipate blood stasis. Conclusion The clinical application in the treatment of coronary heart disease population characteristics and epidemiology of real world Danshen Chuanxiongqin Injection clear, consistent; the clinical dose is mostly higher than that of varieties specification definition, and use a shorter course of treatment, worthy of attention.
引文
[1]WHO.The top 10 causes of death EB/OL.(2018-05-24).http://who.int/mediacentre/factsheets/fs310/en/.
[2]陈伟伟,高润霖,刘力生,等.《中国心血管病报告2017》概要.中国循环杂志,2018,33(1):1-8.
[3]庄逸洋,卢茵茵,李荣,等.基于数据挖掘探讨陈镜合治疗冠心病用药规律[J].广州中医药大学学报,2018,35(2):333-336.
[4]国家卫生计生委合理用药专家委员会,中国药师协会.冠心病合理用药指南[J].中国医学前沿杂志(电子版),2016,8(6):19-108.
[5]HUANG W D,YANG Y F,ZENG Z,et al.Effect of Salvia miltiorrhiza and ligustrazine injection on myocardial ischemia/reperfusion and hypoxia/reoxygenation injury[J].Mol Med Rep,2016,14(5):4537-4544.
[6]王瑜.丹参川芎嗪注射液的临床应用研究进展[J].天津药学,2015,27(4):53-55.
[7]吴嘉瑞,张晓朦,张冰,等.丹参川芎嗪注射液治疗冠心病心绞痛系统评价[J].中国中医药信息杂志,2015,22(3):39-43.
[8]陈秋芳,朱晓峰,韩莉,等.丹参川芎嗪注射液治疗不稳定型心绞痛的Meta分析[J].中成药,2016,38(2):272-277.
[9]谷建光.关联规则算法研究综述[J].电子测试,2016(14):41-42.
[10]章轶立,谢雁鸣,张寅,等.基于医院信息系统电子医疗数据的复方苦参注射液治疗卵巢癌真实世界西药联合用药特征研究[J].辽宁中医杂志,2017,44(11):2255-2259.
[11]高颖,肖东,王辉.不同性别早发冠心病急性心肌梗死的临床差异性探讨[J].中国农村卫生,2017(22):1.
[12]孟菲,李学林.中药注射剂说明书存在问题及分析[J].中国药房,2011,22(27):2587-2589.
[13]SOMEK M.Decision.Support Systems in Health CareVelocity of Apriori Algorithm[J].Stud Health Technol Inform,2017(244):53-57.
[2]陈伟伟,高润霖,刘力生,等.《中国心血管病报告2017》概要.中国循环杂志,2018,33(1):1-8.
[3]庄逸洋,卢茵茵,李荣,等.基于数据挖掘探讨陈镜合治疗冠心病用药规律[J].广州中医药大学学报,2018,35(2):333-336.
[4]国家卫生计生委合理用药专家委员会,中国药师协会.冠心病合理用药指南[J].中国医学前沿杂志(电子版),2016,8(6):19-108.
[5]HUANG W D,YANG Y F,ZENG Z,et al.Effect of Salvia miltiorrhiza and ligustrazine injection on myocardial ischemia/reperfusion and hypoxia/reoxygenation injury[J].Mol Med Rep,2016,14(5):4537-4544.
[6]王瑜.丹参川芎嗪注射液的临床应用研究进展[J].天津药学,2015,27(4):53-55.
[7]吴嘉瑞,张晓朦,张冰,等.丹参川芎嗪注射液治疗冠心病心绞痛系统评价[J].中国中医药信息杂志,2015,22(3):39-43.
[8]陈秋芳,朱晓峰,韩莉,等.丹参川芎嗪注射液治疗不稳定型心绞痛的Meta分析[J].中成药,2016,38(2):272-277.
[9]谷建光.关联规则算法研究综述[J].电子测试,2016(14):41-42.
[10]章轶立,谢雁鸣,张寅,等.基于医院信息系统电子医疗数据的复方苦参注射液治疗卵巢癌真实世界西药联合用药特征研究[J].辽宁中医杂志,2017,44(11):2255-2259.
[11]高颖,肖东,王辉.不同性别早发冠心病急性心肌梗死的临床差异性探讨[J].中国农村卫生,2017(22):1.
[12]孟菲,李学林.中药注射剂说明书存在问题及分析[J].中国药房,2011,22(27):2587-2589.
[13]SOMEK M.Decision.Support Systems in Health CareVelocity of Apriori Algorithm[J].Stud Health Technol Inform,2017(244):53-57.